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Changes in urinary metabolomic 
profile during relapsing renal 
vasculitis
Bahjat Al-Ani1,†, Martin Fitzpatrick2, Hamad Al-Nuaimi1, Alice M. Coughlan3, 
Fionnuala B. Hickey3, Charles D. Pusey4, Caroline Savage1, Christopher M. Benton5, 
Eóin C. O’Brien3, Declan O’Toole6, Ken H. Mok6, Stephen P. Young2 & Mark A. Little7
Current biomarkers of renal disease in systemic vasculitis lack predictive value and are insensitive to 
early damage. To identify novel biomarkers of renal vasculitis flare, we analysed the longitudinal urinary 
metabolomic profile of a rat model of anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Wistar-
Kyoto (WKY) rats were immunised with human myeloperoxidase (MPO). Urine was obtained at regular 
intervals for 181 days, after which relapse was induced by re-challenge with MPO. Urinary metabolites 
were assessed in an unbiased fashion using nuclear magnetic resonance (NMR) spectroscopy, and 
analysed using partial least squares discriminant analysis (PLS-DA) and partial least squares regression 
(PLS-R). At 56 days post-immunisation, we found that rats with vasculitis had a significantly different 
urinary metabolite profile than control animals; the observed PLS-DA clusters dissipated between 
56 and 181 days, and re-emerged with relapse. The metabolites most altered in rats with active or 
relapsing vasculitis were trimethylamine N-oxide (TMAO), citrate and 2-oxoglutarate. Myo-inositol was 
also moderately predictive. The key urine metabolites identified in rats were confirmed in a large cohort 
of patients using liquid chromatography–mass spectrometry (LC-MS). Hypocitraturia and elevated 
urinary myo-inositol remained associated with active disease, with the urine myo-inositol:citrate ratio 
being tightly correlated with active renal vasculitis.
Microscopic polyangiitis (MPA) is a relapsing autoimmune condition characterised by necrotising angiitis usually 
involving the glomerulus and frequently resulting in rapidly progressive kidney failure. It is associated with the 
presence of anti-neutrophil cytoplasm antibodies (ANCA) primarily directed against myeloperoxidase (MPO)1,2. 
The adverse events of therapy may be as big a clinical problem as the disease itself 3. Indeed, over half of those who 
die within the first year of diagnosis do so as a result of infection, presumably due to over-immunosuppression. 
One of the main challenges impinging upon this balancing act between over and under-treatment is accurate 
assessment of disease activity. This is particularly true during follow up when one must always make a judgement 
as to whether disease is active or quiescent. Current biomarkers assisting in this decision include urinalysis to 
detect haematuria and proteinuria, C-reactive protein (CRP) to detect active systemic inflammation, evidence 
of end-organ dysfunction (such as rising serum creatinine), and anti-MPO antibody titre. These are very poor 
biomarkers, being either insensitive (once the creatinine level rises out of the normal range, approximately 30% of 
kidney function has been lost), non-specific (haematuria may derive from other conditions such as urinary tract 
infection or cyclophosphamide-induced cystitis), or of poor predictive value (anti-MPO antibody levels correlate 
very poorly with disease activity4). Therefore, an important unmet need in this relapsing disease is a non-invasive 
test to accurately determine the current level of disease activity.
We used a urinary metabolomic approach to identify potentially useful clinical biomarkers of active renal vas-
culitis. Metabolomics has been successfully employed for the identification of biomarkers in a number of diseases 
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and models, including urinary tract infection, ulcerative colitis, rheumatoid arthritis, multiple sclerosis5–7, 
and both human renal disease and rat models of tubular disease and acute kidney injury8. The experimental 
autoimmune vasculitis (EAV) model in the Wistar-Kyoto (WKY) rat was used to define serial changes in the 
urine metabolome as the disease evolves, and to test the ability of this approach to distinguish between animals 
in remission and relapse. We then investigated whether similar urinary metabolites were informative in patients 
with vasculitis.
Results
Evolution of renal vasculitis and scarring in rats with EAV. WKY rats were immunised with human 
(h) MPO (EAV; n = 12) or human serum albumin (HSA) (Control; n = 7), and assessed at regular intervals for 
a period of 181 days. Urinary markers of active renal vasculitis (haematuria and albuminuria – reported as the 
albumin to creatinine ratio [ACR]) along with anti-MPO titre peaked at 56 days post immunisation (Fig. 1). 
Haematuria and anti-MPO titre declined progressively thereafter while albuminuria remained elevated to a sim-
ilar level throughout the period of observation. Excretory renal function, as quantified by creatinine clearance, 
was reduced in EAV animals at 181 days (Fig. 1D). To assess whether EAV rats developed renal scarring (as is 
observed in patients with MPO-ANCA vasculitis) we stained renal tissue with periodic acid Schiff (PAS)-silver 
and picrosirius red. At 30 weeks post-immunisation (day 210), EAV animals exhibited increased renal scarring 
when compared to the same animal at week 8 (day 56) (Supplemental Fig. S1) and to control animals (data not 
shown). Most of the scarring was in a periglomerular distribution.
Active vasculitis is associated with a distinct urinary metabolite profile. To determine if uri-
nary metabolomic analysis could distinguish between MPO and HSA immunisation groups, serial urines were 
analysed by nuclear magnetic resonance (NMR). Partial least squares-discriminant analysis (PLS-DA) of the 
resulting spectra demonstrated separation of HSA and MPO immunised animals at the point of peak disease 
(day 56) (Fig. 2A). PLS-DA weightings showed that the key peaks associated with separation at this time point 
were trimethylamine N-oxide (TMAO), 2-oxoglutarate and citrate, with contribution also from di-methyl glycine 
(DMG), succinate, homoserine, betaine and myo-inositol (Table 1). We next sought to relate the metabolic data 
obtained at day 56 to the degree of glomerular injury in animals sacrificed 154 days later. We performed a partial 
least squares regression (PLS-R) of urinary NMR spectral bins against the histologically determined glomerular 
damage scores. Despite the long interval between metabolite assay and histological quantification the resulting 
model gave a strong and significant fit (P < 0.05; R2 = 0.9313) (Fig. 2B). Bins were ranked according to their rela-
tive contribution to regression fit, identifying TMAO, 2-oxoglutarate, and succinate as key predictors of glomer-
ular injury (Table 1; Supplemental Fig. S2).
The urine metabolite profile provides an improvement to existing markers. We next sought to 
confirm these putative urinary markers of disease activity against existing standards – dipstick haematuria and 
Figure 1. Change in urine parameters and anti-MPO titre over time . WKY rats were immunised with 
hMPO or HSA, and followed for 181 days. (A) Haematuria peaked at 56 days post immunisation and declined 
steadily thereafter. (B) Albuminuria, as assessed by albumin:creatinine ratio (ACR), also peaked at day 56, 
but remained elevated until day 181. Data are presented as mean + /− s.e.m. (C) Anti-MPO titres declined 
progressively over time and rats with EAV exhibited reduced excretory renal function, as estimated by 
measurement of (D) creatinine clearance. Data are presented as median and IQR.
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ACR. At day 56 ACR and haematuria were significant discriminators between MPO and HSA immunised ani-
mals (Supplemental Table S1). Metabolites DMG and TMAO remained significantly predictive in this analysis. 
All 4 markers were taken forward for logistic regression model building. Haematuria and ACR resulted in a 
model with 90.5% accuracy (Table 2). Adding metabolite markers DMG and TMAO to the model raised the 
predictive accuracy to 95.2%.
We also assessed whether the metabolic changes observed at day 56 persisted, by examining urine samples 
taken at days 112 and 181 post-immunisation (Fig. 2A). Analysis at day 112 showed a reduced PLS-DA model fit 
and this was further reduced by day 181. While 74% of MPO-immunised animals were correctly classified at day 
181, 60% of HSA-immunised animals were misclassified using this model.
Induction of relapse in EAV animals. At 26 weeks post initial immunisation (day 181), EAV rats were 
re-treated with soluble hMPO plus LPS (EAV relapse; n = 7) or saline (EAV no relapse; n = 7). In the relapse 
animals, the decline in anti-MPO titre and haematuria was halted, but there was no significant difference in 
absolute levels compared to controls (data not shown). The degree of glomerulonephritis was similar between 
EAV relapse animals (sacrificed on day 210) and animals sacrificed at day 56, while there was virtually no severe 
glomerular injury or crescents in the non-relapsed animals (Fig. 3A,C). We quantified alveolar haemorrhage by 
measuring the amount of respective lung section staining blue with Perl’s stain, which detects intra-vital depos-
ited iron (Fig. 3B,D–F). Blue staining cells (presumed to be haemosiderin-laden macrophages) were present 
in the walls of the alveoli (Fig. 3D). EAV relapse animals displayed significantly higher levels of blue staining 
than HSA-immunised animals (Fig. 3B, E-F). There was a non-significant trend towards greater staining in EAV 
relapse animals compared to EAV non-relapsed animals (Fig. 3B).
Induction of relapse is associated with a partial re-emergence of the vasculitic urine metabolite 
profile. Having determined the phenotype of relapse using established histological markers, we sought to 
Figure 2. Urinary metabolite profile of rats with EAV at the point of peak disease, during remission and 
following induction of relapse. (A) PLS-DA on 2 Latent variables at several time points during the evolution 
of EAV (day 56, day 112, day 181 (pre relapse) and day 210 (post relapse)) discriminating between (● ) MPO 
(n = 16) and (○ ) HSA (n = 11) groups, and between MPO re-stimulation (◓, n = 6) or control (saline)  
re-stimulation (○, n = 7) of EAV animals. MPO and HSA separate on 2 LVs following stimulation; this 
separation is largely lost by day 112 and 181, with re-emergence following induction of relapse. Haematuria 
data are presented as mean + /− s.e.m. (B) PLS-R of binned 1D NMR spectra of rat urine against histological 
glomerular damage score identifies key urine metabolite markers predictive of damage at day 56 (upper plot) 
and day 210 (lower plot). The correlation plot shows predicted vs. observed damage scores using N bins.
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assess if this was mirrored by the urinary metabolite profile 29 days post induction of relapse (day 210). Analysis 
of urine samples indicated a return to separation by PLS-DA model (Fig. 2A). The metabolic markers were 
broadly similar to those observed at day 56, with citrate and 2-oxoglutarate being the strongest discriminators 
between the two groups (Table 1). However, TMAO, while present, was now ranked considerably lower. As 
before, we used PLS-R analysis to relate metabolites to histological damage using histological glomerular damage 
score on tissue obtained one day after the urine collection. This confirmed the presence of the same metabolites 
(Fig. 2B, Supplemental Fig. 2) with TMAO the strongest correlate of glomerular injury by PLS-R. Dimethylamine, 
citrate, maltose and 2-oxoglutarate were also discriminatory with less power.
Metabolite markers improve disease activity prediction over haematuria and proteinuria. To 
assess whether addition of urine metabolites to existing markers (haematuria and ACR) improved the ability to 
detect relapse, we tested for differences between MPO and control relapsed groups and went on to build a binary 
logistic model as performed at day 56 (Supplemental Table S2; Table 3). Of note, haematuria and ACR were not 
significantly different between relapse and control groups at this disease point. Of the proposed urine metabolite 
markers only 2-oxoglutarate was significantly different. Haematuria, ACR and 2-oxoglutarate were taken forward 
into a binary logistic model. Here haematuria and ACR performed poorly, with a prediction accuracy of 58.3% 
(p = 0.665). Addition of 2-oxoglutarate improved predictive performance and accuracy; however, the strongest 
model used 2-oxoglutarate alone, reaching 83.3% accuracy for prediction (p < 0.05).
Metabolite markers identified in EAV are detectable in patient urine by LC-MS. We then sought 
to apply the unbiased metabolomic findings of the animal study to assess whether a targeted metabolomic anal-
ysis could identify active renal vasculitis in patients (Supplemental Table S3). Nine of the metabolites identified 
from the EAV study were selected and targeted for LC-MS analysis of patient urine, all of which were successfully 
identified and quantified. Four of the targeted metabolites were found by PLS-DA and ANOVA to be significantly 
different between patients with active renal vasculitis and those in remission — myo-inositol, citric acid, maltose 
ppm Metabolite
D56 D210
PLS-DA weight
PLS-R 
score PLS-DA weight
PLS-R 
score
3.2680, 3.2739 TMAO ▴0.63 11.68 ▴0.17 12.92
2.4466, 3.0157 2.4349, 2.4408 2-Oxoglutarate ▴0.23 11.21 ▴0.37 3.50
2.6989, 2.5757 2.5522 Citrate ▾ 0.17 5.43 ▾ 0.39 3.58
2.9277 Dimethylglycine ▴0.14 3.15
2.4114 Succinate ▾ 0.13 10.44
3.8547 Homoserine ▴0.13
3.2621 Betaine ▴0.11 3.03
 3.4323, 3.7021, 3.8253 Maltose/Glucose 5.07
 3.8312 Maltose 3.65
2.5464 Beta-alanine ▴0.15
2.6930 Carnosine ▴0.14
2.7282, 2.7048 Dimethylamine ▴0.13 3.92
3.6082, 3.2503 myo-Inositol ▴0.10 1.64 2.25
Table 1.  Urinary metabolite profile of rats with EAV at day 56 and day 210. Top-ranked metabolites are 
shown for analysis at each time point. All comparisons are control versus test; therefore ▴ indicates increase in 
MPO immunised (v HSA immunised) rats at day 56, and MPO relapsed (v saline treated, MPO-immunised 
animals) at day 210. The top contributing metabolites in each analysis are highlighted. Shown values are weights 
for PLS-DA and scores for PLS-R.
Predictors B S.E. Wald df Sig. Exp (B)
Model Accuracy
HSA MPO All p
Haematuria 1.771 0.963 3.381 1 0.066 5.875
75 100 90.5 < 0.001
ACR 0.014 0.03 0.217 1 0.642 1.014
Haematuria 2.212 1.251 3.127 1 0.077 9.133
87.5 100 95.2 0.001
ACR − 0.004 0.063 0.005 1 0.946 0.996
DMG 2.029 18.514 0.012 1 0.913 7.604
TMAO 4.311 5.6 0.593 1 0.441 74.507
Table 2.  Binary logistic regression of ANOVA selected metabolites and existing markers at day 56 in 
rat urine. A predictive model built with existing markers (top panel) is strongly predictive (90.5% accuracy 
p < 0.001) of HSA and MPO immunisation status. Adding metabolites (lower panel) raises prediction capacity 
by 5%.
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and succinate (Fig. 4A; Table 4). These metabolites, all of which had a variable importance in the project (VIP) 
score> 0.25 (Fig. 4B), and existing clinical markers were taken forward for subsequent analysis.
Figure 3. Effect of relapse induction. WKY rats were immunised with hMPO or HSA and sacrificed at day 56 
or day 210, the latter following treatment with either LPS + MPO (Relapse) or saline (Control) at day 181. (A) The 
degree of glomerulonephritis was scored blindly at 56 days and 210 days. (B) Lung haemorrhage was assessed by 
staining lung sections with Perl’s stain, which shows iron deposition as blue, and quantifying the degree of blue 
staining with image analysis. Data are presented as median and IQR. (C) Representative image of a renal section 
from a severely affected rat relapsed with MPO and LPS. There is a marked interstitial infiltrate, focal necrotising 
crescentic glomerulonephritis and tubular dilatation (H&E, x100). (D) Representative image depicting brown-
staining haemosiderin-laden alveolar macrophages in a lung section from a relapsed animal (H&E, x400).  
(E,F) Representative images from Perl’s stained lung sections from (E) a control and (F) a relapsed animal (x10).
Predictors B S.E. Wald df p OR
Model Accuracy
MPO Control Total p
Haematuria 0.46 0.909 0.256 1 0.613 1.584
20 85.7 58.3 0.665
ACR − 0.004 0.005 0.718 1 0.397 0.996
Haematuria 0.171 1.168 0.021 1 0.884 1.187
80 85.7 83.3 0.122ACR − 0.003 0.01 0.074 1 0.785 0.997
2-OG − 13.29 8.447 2.475 1 0.116 0
2-OG − 13.36 7.432 3.231 1 0.072 0 80 85.7 83.3 0.017
Table 3.  Binary logistic regression of ANOVA selected metabolite and existing markers in MPO 
immunised animals at day 210. A predictive model built with existing markers is poorly predictive (58.3% 
accuracy p = 0.665) of relapse status in EAV (top panel). Adding 2-oxoglutarate (2-OG) to the model improved 
prediction and p values slightly but not to significance (middle panel). Removal of the current biomarkers, 
leaving 2-oxoglutarate alone resulted in a statistically significant model predicting 83.3% of relapse status (lower 
panel). OR = Odds ratio.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:38074 | DOI: 10.1038/srep38074
The myo-inositol:citric acid ratio is highly predictive of active renal vasculitis. Urine metab-
olomic markers were added to a binary logistic regression model to test the ability to predict active renal vas-
culitis among patients with known vasculitis. The resulting model consisted of two metabolites – citric acid 
and myo-inositol (Table 5). Additional models were built for comparison of existing markers – CRP, estimated 
glomerular filtration rate (eGFR) and protein:creatinine ratio (PCR). Existing marker prediction accuracy for 
identification of active renal vasculitis was 89.6%, metabolites alone was 91.7%, and a model combining existing 
markers with metabolites was 95.8%. The accuracy of the combined model was confirmed using a bootstrap-
ping analysis (Supplemental Table S4). Stratification by ANCA specificity (proteinase 3 (PR3) v MPO) did not 
affect predictive capacity (data not shown). A Receiver Operator Characteristic (ROC) curve was constructed to 
assess the performance of the metabolite model in identifying active renal vasculitis (Fig. 4C). As citric acid was 
decreased in the urine of patients with active renal vasculitis, while myo-inositol was elevated, we investigated the 
association between the myo-inositol:citric acid ratio and disease state (Fig. 5A). This ratio was markedly elevated 
in active renal vasculitis when compared to patients in remission, healthy controls, and disease controls; a smaller 
signal was also observed in patients with active extra-renal vasculitis. As patients received increasing amounts of 
therapy the myo-inositol:citrate ratio appeared to decline (Supplemental Fig. 3) and patients classified blindly as 
in remission but receiving induction therapy with cyclophosphamide or rituximab had a slightly elevated value. 
This probably reflects persistent sub-clinical disease in the context of ongoing induction therapy. To confirm the 
findings further against urine from patients with kidney infection, we used NMR to compare to the myoinosi-
tol:citrate ratio in active renal vasculitis (Fig. 5B), which confirmed the specificity of the LC-MS findings.
Discussion
Although the ANCA test is an excellent biomarker in diagnosing systemic vasculitis, it performs poorly when 
determining whether the vasculitic process is active or not. The unmet need in this field is a test that determines 
when glomerular inflammation has stopped (allowing discontinuation of induction therapy), and that provides a 
Figure 4. Urinary metabolite profile of patients with active and remission vasculitis. (A) PLS-DA of binned 
LS-MS spectra of human urine samples from patients with active renal vasculitis ( , n = 28) against cases in 
remission ( , n = 104). PLS-DA weightings identify key metabolites associated with active renal vasculitis.  
(B) Receiver operator characteristic curve showing the prediction accuracy of the binary logistic model based 
on citric acid and myo-Inositol with area under the curve (AUC) = 0.922 (95% CI 0.849–0.970, p = 0.001).  
(C) Variable importance in the project (VIP) scores summarising the predictive value of each metabolite in 
identifying active renal vasculitis. Values above 1 indicate a useful marker.
Sum of Squares Mean Square F Sig.
myo-Inositol 0 0 55.879 0
Citric acid 0.044 0.044 12.379 0.001
Maltose 0 0 8.357 0.005
Succinate 0 0 5.603 0.019
2-oxoglutarate 0 0 1.705 0.194
Betaine 0.002 0.002 1.124 0.291
TMAO 0.001 0.001 0.193 0.661
Glutaric acid 0 0 0.187 0.666
Dimethylglycine 0 0 0.031 0.861
Table 4.  ANOVA of all creatinine-normalised metabolites analysed in human urine by LC-MS, ranked by 
their association with active renal vasculitis. Summary statistics shown are for between-groups comparisons.
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sensitive means of detecting re-emergence of glomerulonephritis in the setting of relapsing disease. We modelled 
the chronic relapsing phenotype of MPO-ANCA vasculitis in an effort to identify urinary metabolites that reflect 
active inflammation more accurately than measurement of urinary blood and protein. WKY rats immunised with 
hMPO developed pauci-immune glomerulonephritis with peak effect at day 56, after which the immune response 
and glomerular damage declined progressively over the subsequent 17 weeks. Although there was no significant 
increase in haematuria after re-challenge with MPO plus LPS, when the kidneys were analysed 154 days later, 
the glomerular injury resembled that at day 56, whereas non-relapsed animals at the same time point had very 
mild glomerular disease. We went on to analyse the urinary metabolomic profile at various time points during 
the disease course and found that the marked separation between MPO and HSA immunised animals at day 56 
had largely disappeared by day 181 (immediately prior to re-challenge), and re-emerged after re-challenge with 
the antigen and LPS. Addition of metabolite markers to measurement of haematuria and proteinuria increased 
the correct classification of animals into relapsed versus non-relapsed. We confirmed our findings in patients 
with vasculitis by using LC-MS to analyse a targeted selection of the metabolites that we had identified in the rat. 
Although there were some differences between the rat and human data, this targeted approach allowed us to iden-
tify myo-inositol and citrate, and more specifically the ratio between these two metabolites, as key biomarkers 
associated with active renal vasculitis.
Existing measure B S.E. Wald Sig. Std OR 95% CI
CRP 0.011 0.007 2.746 0.004 2.288 1.31 4.00
eGFR − 0.059 0.03 3.89 < 0.001 0.367 0.21 0.63
PCR 0.017 0.007 5.349 0.007 3.238 1.38 7.62
Model constant −0.486 1.457 0.111 0.739 0.156
Metabolite B S.E. Wald Sig. Std OR 95% CI
Citric acid − 39.65 11.8 11.186 0.001 0.067 0.014 0.33
myo-inositol 6039 1536.5 15.452 < 0.001 9.245 3.05 28.0
Model constant −0.046 0.675 0.005 0.945 0.955
Table 5.  Binary logistic models using existing biomarkers and novel metabolites in human urine to 
predict active renal vasculitis. Existing biomarkers (CRP, eGFR, PCR) were used for the base model. Identified 
metabolite predictors were selected by forward selection from the identified candidates (myo-Inositol, citric 
acid, glycolic acid, maltose and succinate) based on their ability to significantly improve the model. Std 
OR = Standardised odds ratio.
Figure 5. Utility of the urine myoinositol:citrate ratio in identifying active vasculitis. (A) Myo-
inositol:citrate ratio as determined by LC-MS according to diagnostic groupings. (B) Reverse confirmation of 
urine myo-inositol:citrate ratio using NMR, with inclusion of patients with urine infection (UTI), N = 3–4 per 
group. A value from a patient with remission vasculitis is shown for comparison. Bars depict median and 90th 
centile. AAV (R) = AAV in remission. ****p < 0.001, *p < 0.05.
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Our analysis showed highest rank bins in the acute response were associated with TMAO, a previously iden-
tified marker of renal medullary injury9,10, 2-oxoglutarate, citrate, DMG and succinate. TMAO is a product of 
the oxidation of trimethylamine derived from choline metabolism. Its role as a marker of renal medullary injury 
may be an indicator of the tubulointerstitial nephritis that usually co-exists with the glomerular injury in this rat 
model.
Citrate, succinate and 2-oxoglutrate are major citric acid cycle metabolites and, although we cannot prove 
this with our data, a possible indicator of high energy demands, either resulting from renal repair or infiltrat-
ing immune cells. Of particular relevance in this respect is the recent discovery of aerobic glycolysis (“Warburg 
effect”) in activated immune cells, such as M1 macrophages and Th17 lymphocytes11,12. Under inflammatory 
conditions, the citric acid cycle appears to be arrested in these cells, with accumulation of succinate and other 
intermediates. The citric acid cycle signal evident in rats with active disease, particularly the consistent finding of 
2-oxoglutarate, is consistent with the concept of aerobic glycolysis in infiltrating glomerular leukocytes, but would 
require direct assay of these metabolites in renal tissue to delineate further.
Although it was important to demonstrate a distinct metabolic profile in acute disease, the primary focus 
of this work was on changes in the urine metabolome as the pathology dissipated and relapsed. To model this 
we defined remission at 181 days post-immunisation with MPO. By this time the EAV and control groups were 
virtually inseparable by PLS-DA of urinary metabolites. At this point the EAV rats were re-stimulated with MPO 
or mock-stimulated with saline and urine samples were compared 29 days later. Re-stimulation with MPO was 
associated with a urine metabolic profile similar to that at day 56. Citrate and 2-oxoglutarate were the strongest 
differentiators of relapse, with TMAO being no longer predictive. However, despite this finding, PLS-R against 
glomerular damage score again showed TMAO to be the strongest predictor of histological injury, suggesting that 
the urinary TMAO signal may reflect the totality of renal parenchymal injury rather than recurrence of glomeru-
lar inflammation in the context of experimental vasculitis flare. We next sought to rate theses metabolites against 
existing biomarkers of renal damage (ACR and haematuria) using binary logistic models. While haematuria 
and ACR proved strong predictors of active disease at day 56, they proved a poor marker of relapsing disease. 
In relapsing disease, we identified a single predictive metabolite, 2-oxoglutarate, which successfully identified 
relapsed animals.
Having identified a set of metabolites offering diagnostic potential in the EAV model, we sought to confirm 
this in human vasculitis. A small number of metabolites were analysed based on the unbiased rat study allowing 
us to use a large number of urine samples comprising several different experimental groups and to use a different 
technique, LC-MS, which is more sensitive than NMR. Although, there were common metabolites between rat 
and human samples, there were notable differences, such as the absence of TMAO, DMG and 2-oxoglutarate in 
the human analyses. However, the reciprocal association between urinary citrate/myo-inositol and active vascu-
litic glomerulonephritis transferred to the human setting, performing better than existing markers CRP, eGFR 
and PCR. We did not obtain sufficient data on haematuria in the included patients to include this in the analysis. 
The combination of metabolites, CRP, eGFR, and PCR correctly allocated cases in over 95% of cases and the 
ratio of citrate:myo-inositol separated active renal vasculitis from other groups with a high degree of precision. 
A small signal was observed with the metabolite ratio in patients with active extra-renal vasculitis despite having 
no evidence of glomerulonephritis, suggesting that the urinary value also partially reflects filtered citrate and 
myo-inositol.
To conclude, we have demonstrated the predictive ability of a pair of urine metabolite markers, citrate and 
myo-inositol, that may have clinical value in the diagnosis of active renal vasculitis.
Methods
Ethics Statement. All animal experiments were performed according to UK home office regulations under 
project license number 400/3228, and with full approval from the University of Birmingham Ethical Review 
Committee. Human urine samples were obtained from the Irish Rare Kidney Disease (RKD) Biobank, and writ-
ten informed consent was obtained from all individuals. The RKD Biobank has full approval from the Trinity 
College Dublin Institutional Review Board and Ethics Committee, and approval from each of the individual 
hospitals from which samples were obtained (St. James’ hospital, Tallaght hospital and Beaumont hospital). All 
experiments were carried out in accordance with the approved guidelines.
Induction of EAV and relapse. Female WKY rats (Charles River, UK) (100–130 g) were immunised on day 
0 with a total of 3.2 mg/kg hMPO (a kind gift from Biovitrum, Stockholm, Sweden) or human serum albumin 
(HSA) in an equal volume of complete Freund’s adjuvant (CFA, Sigma-Aldrich, UK) at 2 intramuscular and 2 
subcutaneous sites. All animals received 1μ g of pertussis toxin i.p. (Sigma-Aldrich, UK) on days -5 and 0, and 
1500 EU/g lipopolysacharide (LPS) on days 7, 28, and 35. Booster doses (100 μ g/kg) of soluble MPO or HSA 
were administered i.p. on days 21 and 35. 181 days post-immunisation we induced relapse with LPS (1500 EU/g) 
plus 100 μ g/kg MPO or HSA in controls. Non-relapsed animals received saline. Animals were culled 29 days 
post-relapse.
Assessment of disease phenotype. We used haematoxylin and eosin (H&E) and periodic acid Schiff 
(PAS)-stained sections to quantify glomerulonephritis and tubulitis. 50 glomeruli per section were scored blind 
as normal, abnormal or severely diseased. Picrosirius red staining of tissue sections was used to quantify renal 
scarring. Embedded kidney sections were dewaxed in xylene and rehydrated through a series of graded alcohols 
to water. Slides were incubated overnight with 0.1% Sirius red (Sigma-Aldrich, UK), quickly dipped in 0.01 M 
hydrochloric acid and dehydrated with serial ethanol concentrations without water. The overall degree of staining 
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was quantified in Image J after excluding blood vessels. Kidney fibrosis was visualised by PAS stain with the addi-
tion of methenamine silver solution.
We used Perl’s stain to identify haemosiderin laden macrophages in the lung13 allowing differentiation of pre 
and post-mortem bleeding. Embedded lung sections were dewaxed and hydrated to distilled water. Slides were 
placed for 20 minutes in freshly prepared working solution (equal volume of 2% hydrochloric acid and 2% potas-
sium ferrocyanide) and washed in tap water. Sections were dehydrated with alcohol and cleared with xylene. An 
automated staining machine (Dako Artisan) was used to perform Perl’s stain. Images were captured and analysed 
in Aequitas IA image analysis software (Dynamic Data Links, Cambridge, UK).
Quantification of urinary metabolites by NMR. Using metabolic cages, rat urine samples were col-
lected for 24 hours in containers with 200 mM boric acid added to prevent bacterial growth. The presence of 
blood and leukocytes was assessed by dipstick, with a semi-quantitative score ranging from 0–4. Urine samples 
were sterilised by filtration through a 0.22 μ m pore. We measured urinary albumin excretion rate by Nephrat 
ELISA (Exocell, Philadelphia, USA), and creatinine was measured by the modified Jaffe reaction in an autoana-
lyser. Urinary albumin was reported as the albumin to creatinine ratio (ACR). Samples for NMR were buffered 
with phosphate buffer (100 mM), containing 10% D2O and 0.5 mM TMSP and the pH adjusted (twice over 
30 mins) to pH 7.0. Samples were then centrifuged at 13000 g for 5 minutes14. One-dimensional1H spectra were 
acquired at 300 K using a standard spin-echo pulse sequence with water suppression and excitation sculpting 
on a Bruker DRX 500 MHz NMR spectrometer equipped with a cryoprobe. Data were calibrated with respect 
to the trimethylsilyl propionate (TMSP) signal. Spectra were read into Metabolab15 software in Matlab (R2011a, 
The Math Works, Natick MA) and segmented into 0.005 ppm chemical shift ‘bins’, and spectral areas within 
each bin were integrated. When used in this paper ppm refers to the spectral position of a given peak, not the 
quantity of that metabolite. Spectra were corrected for baseline offset and normalised to a total spectral area 
of unity and a generalised log transformation was applied (26). Binned data were compiled into a matrix and 
values were normalised using Probabilistic Quotient Normalization (PQN) to account for volume effects16. A 
similar approach, using two-dimensional NMR spectroscopy, was used to compare myoinositol and citrate lev-
els in patients with active renal AAV, urine infection and healthy controls. Quantitative 1H-13C HSQC (heter-
onuclar single quantum correlation) spectra were acquired on an Agilent Technologies 18.8 T (800 MHz) DD2 
Premium Compact spectrometer with a triple resonance 5 mm enhanced cold probe. Spectra were collected at 
25 °C with 12 scans, an initial delay of 3.0 s, a 90° pulse width of 12.1 μ s, and an acquisition time of 0.3 s with 
broadband decoupling.
Quantification of human urinary metabolites by LC-MS. Human urine samples were obtained from 
the RKD Biobank (Supplemental Table S3) and comprised patients with small vessel vasculitis (N = 143), healthy 
controls (N = 45), and non-vasculitic kidney disease controls (N = 23, comprising diabetic nephropathy (n = 5), 
nephrotic syndrome (n = 5), ischemic nephropathy (n = 5), renal tubular acidosis (n = 2), interstitial nephritis 
(n = 1) and inflammatory extra-renal disease (endovascular stent infection, diverticulitis, ulcerative colitis, SLE, 
Henoch-Schonlein purpura). Patients with vasculitis were categorised into remission and active disease using 
the Birmingham Vasculitis Activity Score (BVAS), with a BVAS score of > 1 indicating active disease, and a 
positive score in one or more renal BVAS items indicating active renal disease. The UHPLC system consisted of 
Agilent 1290 Infinity Binary Pump, Sampler, Thermostat and Thermostatted Column Compartment (Agilent 
Technologies, Waldbronn, Germany). Analytes were retained using an Xbridge Amide column (50 × 2.1 mm i.d., 
3.5 μ m average total particle diameter; Waters, Cheshire, UK). The column oven temperature was maintained at 
40 °C, the autosampler tray at 10 °C and injection volume was 1 μ L. Mobile phase flow rate was 0.450 mL/min. 
Elution programme: 0–1 min 5% A (95% B); 1–7 min 25% A (75% B); 7–7.5 min 50% A (50% B); 7.5–10 min70% 
A (30% B); 10–15 min 5% A (95% B). Eluent A: aqueous 50 mmol/L ammonium acetate (pH 9.0); eluent B: 
acetonitrile.
The mass spectrometer used was an Agilent 6495 Triple Quad LC-MS (Agilent Technologies, Santa Clara, 
USA) equipped with an Agilent Jet Stream electrospray ionisation source, operated in positive ionisation mode 
(capillary voltage, 2500 V; nozzle voltage, 0 V; capillary gas temperature, 200 °C; capillary gas flow, 15 L/min; 
sheath gas temperature, 400 °C, sheath gas flow, 11 L/min; nebulizer, 40 psi). The collision energies are shown in 
Supplemental Table S5. Nitrogen was used as the collision gas. The data was processed using Agilent MassHunter 
Qualitative analysis software (version B 07.00 SP1), Agilent MassHunter Profinder (version B 06.00) and Mass 
Profiler Professional (version 12.6.1).
Statistical analysis of urinary metabolites. Rat metabolomic datasets were statistically analysed using 
partial-least-squares supervised multivariate methods17. All analysis was performed on binned, mean centred 
spectra using PLS Toolbox (version 5.7) (Eigenvector Research) in Matlab (release 2011a) (Mathworks). PLS-DA 
was cross-validated using Venetian blinds18. PLS weights of individual spectra ppm peaks (reported as absolute 
values) were used to rank the importance of individual bins.
Partial least squares regression (PLS-R) was used to relate metabolic change to glomerular damage score. The 
PLS model was tested to determine the optimal number of latent variables (LVs), thereby maximising signal:noise 
ratio. Metabolites in the resulting LVs were permutation tested to determine the metabolites that were truly 
predictive with the resulting optimal metabolites forward selected to produce a final model. The resulting model 
r2 value indicates a measure of goodness-of-fit for regression and ranked bins by contribution. Bins were then 
identified by manual peak fitting of original spectra using Chenomx NMR suite (Chenomx, Alberta, Canada) 
and MATLAB scripting.
Analysis of human data was performed using SPSS Statistics (version 21, IBM) using a two-step analy-
sis. Metabolite concentrations were scaled to urinary creatinine to reflect typical clinical practice. Metabolite 
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predictors identified by the PLS-DA model with a VIP score > 0.25 were selected and taken forward for binary 
logistic modelling. The resulting binary logistic model was confirmed using bootstrapping to evaluate predictive 
power.
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